This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Milatovic, D.
Right arrow Articles by Fluit, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milatovic, D.
Right arrow Articles by Fluit, A. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2003, p. 400-404, Vol. 47, No. 1
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.1.400-404.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates

D. Milatovic,* F.-J. Schmitz, J. Verhoef, and A. C. Fluit

Eijkman-Winkler Institute for Medical Microbiology, Utrecht, The Netherlands

Received 13 June 2002/ Returned for modification 11 September 2002/ Accepted 15 October 2002

The in vitro activities of tigecycline against 1,924 clinical isolates were examined. The new glycylcycline exhibited excellent activity against all gram-positive cocci (MICs at which 90% of the isolates tested were inhibited [MIC90s], <=1 µg/ml). In addition, it was also very potent against most members of the Enterobacteriaceae, with most MIC90s being <=2 µg/ml. Among the nonfermenters, Acinetobacter spp. and Stenotrophomonas maltophilia are included in the in vitro spectrum of tigecycline activity.

* Corresponding author. Mailing address: Eijkman-Winkler Institute for Medical Microbiology, University Hospital Utrecht, G 04.614, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Phone: 31 30 2507625. Fax: 31 30 2541770. E-mail: d.milatovic{at}azu.nl.

Antimicrobial Agents and Chemotherapy, January 2003, p. 400-404, Vol. 47, No. 1
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.1.400-404.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kelesidis, T., Karageorgopoulos, D. E., Kelesidis, I., Falagas, M. E. (2008). Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62: 895-904 [Abstract] [Full Text]  
  • Malli, E., Spiliopoulou, I., Kolonitsiou, F., Neocleous, Ch., Klapsa, D., Pantelidi, K., Panopoulou, M., Grapsa, S., Alepopoulou, E., Neonakis, I., Alexiou-Daniel, S., Bakola, D., Koutsia-Carouzou, C., Malamou-Lada, H., Zerva, L., Vlahaki, E., Kartali-Ktenidou, S., Anastassiou, E., Petinaki, E. (2008). In vitro activity of tigecycline against Gram-positive cocci: a multicentre study in Greece. J Antimicrob Chemother 62: 1158-1160 [Full Text]  
  • (2008). What role for {blacktriangledown}tigecycline in infections?. DTB 46: 62-64 [Abstract] [Full Text]  
  • Moland, E. S., Craft, D. W., Hong, S.-g., Kim, S.-y., Hachmeister, L., Sayed, S. D., Thomson, K. S. (2008). In Vitro Activity of Tigecycline against Multidrug-Resistant Acinetobacter baumannii and Selection of Tigecycline-Amikacin Synergy. Antimicrob. Agents Chemother. 52: 2940-2942 [Abstract] [Full Text]  
  • Brown, S. D., Traczewski, M. M. (2007). Comparative In Vitro Antimicrobial Activity of Tigecycline, a New Glycylcycline Compound, in Freshly Prepared Medium and Quality Control. J. Clin. Microbiol. 45: 2173-2179 [Abstract] [Full Text]  
  • Scheetz, M. H., Qi, C., Warren, J. R., Postelnick, M. J., Zembower, T., Obias, A., Noskin, G. A. (2007). In Vitro Activities of Various Antimicrobials Alone and in Combination with Tigecycline against Carbapenem-Intermediate or -Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 1621-1626 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2006). Comparative In Vitro Susceptibilities of 396 Unusual Anaerobic Strains to Tigecycline and Eight Other Antimicrobial Agents. Antimicrob. Agents Chemother. 50: 3507-3513 [Abstract] [Full Text]  
  • Morosini, M.-I., Garcia-Castillo, M., Coque, T. M., Valverde, A., Novais, A., Loza, E., Baquero, F., Canton, R. (2006). Antibiotic Coresistance in Extended-Spectrum-{beta}-Lactamase-Producing Enterobacteriaceae and In Vitro Activity of Tigecycline.. Antimicrob. Agents Chemother. 50: 2695-2699 [Abstract] [Full Text]  
  • Kasbekar, N. (2006). Tigecycline: A new glycylcycline antimicrobial agent.. Am J Health Syst Pharm 63: 1235-1243 [Abstract] [Full Text]  
  • Kronvall, G., Karlsson, I., Walder, M., Sorberg, M., Nilsson, L. E. (2006). Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation. J Antimicrob Chemother 57: 498-505 [Abstract] [Full Text]  
  • Jones, C. H., Tuckman, M., Howe, A. Y. M., Orlowski, M., Mullen, S., Chan, K., Bradford, P. A. (2006). Diagnostic PCR Analysis of the Occurrence of Methicillin and Tetracycline Resistance Genes among Staphylococcus aureus Isolates from Phase 3 Clinical Trials of Tigecycline for Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 50: 505-510 [Abstract] [Full Text]  
  • Breedt, J., Teras, J., Gardovskis, J., Maritz, F. J., Vaasna, T., Ross, D. P., Gioud-Paquet, M., Dartois, N., Ellis-Grosse, E. J., Loh, E., for the Tigecycline 305 cSSSI Study Group, (2005). Safety and Efficacy of Tigecycline in Treatment of Skin and Skin Structure Infections: Results of a Double-Blind Phase 3 Comparison Study with Vancomycin-Aztreonam. Antimicrob. Agents Chemother. 49: 4658-4666 [Abstract] [Full Text]  
  • Livermore, D. M. (2005). Tigecycline: what is it, and where should it be used?. J Antimicrob Chemother 56: 611-614 [Abstract] [Full Text]  
  • Bradford, P. A., Petersen, P. J., Young, M., Jones, C. H., Tischler, M., O'Connell, J. (2005). Tigecycline MIC Testing by Broth Dilution Requires Use of Fresh Medium or Addition of the Biocatalytic Oxygen-Reducing Reagent Oxyrase To Standardize the Test Method. Antimicrob. Agents Chemother. 49: 3903-3909 [Abstract] [Full Text]  
  • Petersen, P. J., Bradford, P. A. (2005). Effect of Medium Age and Supplementation with the Biocatalytic Oxygen-Reducing Reagent Oxyrase on In Vitro Activities of Tigecycline against Recent Clinical Isolates. Antimicrob. Agents Chemother. 49: 3910-3918 [Abstract] [Full Text]  
  • Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56: 470-480 [Abstract] [Full Text]  
  • Betriu, C., Culebras, E., Gomez, M., Rodriguez-Avial, I., Picazo, J. J. (2005). In vitro activity of tigecycline against Bacteroides species. J Antimicrob Chemother 56: 349-352 [Abstract] [Full Text]  
  • Sun, H. K., Ong, C. T., Umer, A., Harper, D., Troy, S., Nightingale, C. H., Nicolau, D. P. (2005). Pharmacokinetic Profile of Tigecycline in Serum and Skin Blister Fluid of Healthy Subjects after Multiple Intravenous Administrations. Antimicrob. Agents Chemother. 49: 1629-1632 [Abstract] [Full Text]  
  • Muralidharan, G., Micalizzi, M., Speth, J., Raible, D., Troy, S. (2005). Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects. Antimicrob. Agents Chemother. 49: 220-229 [Abstract] [Full Text]  
  • Betriu, C., Culebras, E., Rodriguez-Avial, I., Gomez, M., Sanchez, B. A., Picazo, J. J. (2004). In Vitro Activities of Tigecycline against Erythromycin-Resistant Streptococcus pyogenes and Streptococcus agalactiae: Mechanisms of Macrolide and Tetracycline Resistance. Antimicrob. Agents Chemother. 48: 323-325 [Abstract] [Full Text]  
  • Cercenado, E., Cercenado, S., Bouza, E. (2003). In Vitro Activities of Tigecycline (GAR-936) and 12 Other Antimicrobial Agents against 90 Eikenella corrodens Clinical Isolates. Antimicrob. Agents Chemother. 47: 2644-2645 [Abstract] [Full Text]  
  • Cercenado, E., Cercenado, S., Gomez, J. A., Bouza, E. (2003). In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 52: 138-139 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»